key: cord-0056766-i183uaxb
authors: Medranda, Giorgio A.; Case, Brian C.; Wermers, Jason P.; Morrison, Natalie; Yerasi, Charan; Forrestal, Brian J.; Chezar-Azerrad, Chava; Waksman, Ron
title: Review of interventional late breaking trials from AHA Scientific Sessions 2020 Virtual Meeting
date: 2021-03-01
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2021.02.020
sha: cb20439a4855d26adf8a32e3f51a5d1633339cdf
doc_id: 56766
cord_uid: i183uaxb

nan

In 2020, the coronavirus disease 2019 (COVID-19) pandemic has prompted every major cardiology conference to cancel or go virtual since March 2020, including the American Heart Association's (AHA) annual Scientific Sessions. The virtual meetings have allowed more people than ever to participate in a robust online experience. In this article, we present a brief overview of selected late-breaking clinical trials presented at the AHA Scientific Sessions 2020 Virtual

Meeting that carry significant clinical implications. All that being said, it remains uncertain whether omega-3 fatty acids reduce cardiovascular risk or prevent heart disease in the general population. A CA formulation of EPA and DHA (omega-3 CA, brand name Epanova) has been previously documented to have favorable effects on lipid and inflammatory markers. It is administered as a free fatty acid not requiring hydrolysis by pancreatic lipase during intestinal absorption, eliminating the need for co-administration with a high-fat diet and resulting in greater bioavailability compared with standard omega-3 ethyl ester formulations.

The investigators of the STRENGTH trial assessed the effects of omega-3 CA on cardiovascular outcomes. A. Michael Lincoff, MD, of Cleveland Clinic, presented the results of the STRENGTH trial, which were simultaneously published online in JAMA. [1, 2] STRENGTH was a double-blind, randomized, multicenter, international trial comparing omega-3 CA (4 gm daily, n=6539) with a matching corn oil placebo (n=6539) in statin-treated participants with high cardiovascular risk, hypertriglyceridemia (triglyceride levels ≥180 mg/dL and <500 mg/dL) and low levels of high-density lipoprotein cholesterol (HDL-C <42 mg/dL for men or <47 mg/dL for women). The primary efficacy measure was a composite of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, coronary revascularization and hospitalization for J o u r n a l P r e -p r o o f Journal Pre-proof unstable angina (UA). Changes in lipid and inflammatory biomarkers, as well as safety and tolerability were evaluated.

The study began in 2014 and was stopped slightly early, in January 2020, after an independent Data and Safety Monitoring Board recommended for futility because preliminary results of the study deemed it unlikely to prove the benefit of omega-3 CA medication. Over a median followup time of approximately 3 years, 1580 patients experienced at least one cardiac event. There were no significant differences in the number of patients experiencing cardiac events between the two treatment groups. Additionally, atrial fibrillation (AF) occurred more frequently among patients taking the omega-3 CA medication than in those receiving the control corn oil. , showed that the risk of ischemic events, including cardiovascular-related death, was significantly lower among those who received 2 grams of icosapent ethyl twice daily than among those who received placebo. [3] Icosapent ethyl is a highly purified EPA omega-3 acid in ethyl ester form. symptoms were reinduced by statin or placebo tablets. The investigators hypothesized that more than 50% of patients' symptom burden is "nocebo" rather than pharmacological and that, at 6 months, the majority of participants would either be taking statins or would have declined statins for reasons other than perceived side effects.

The study recruited 60 participants in London between June 2016 and March 2019 who had previously stopped taking statins because of side effects. The subjects received 12 1-month medication bottles in a random sequence: four contained 20 mg of atorvastatin, four contained placebo, and four were empty. Participants reported the intensity of their symptoms daily via a smartphone app on a scale of 0 (no symptoms) to 100 ("worst imaginable"). If symptoms became intolerable, the subjects could stop taking tablets that month. One key inclusion criterion was that study participants needed to have reported feeling symptoms within 2 weeks that were so bad they stopped the medication. This would make it more likely that they might feel those symptoms again within a 1-month time period in the study. The primary endpoint was the "nocebo ratio," that is, the ratio of symptom intensity induced by statin tablets that was also induced by taking a placebo.

The nocebo ratio in the study was 0.90, meaning that 90% of the symptom burden stemming from taking statins was also prompted by placebo. Mean symptom intensity was 6.3 during no- Howard concluded that patients must be taken seriously when they report side effects of medications because they really feel them but that exploring these side effects can make all the difference. The novel n-of-1 trial design comprising active treatment, placebo and no treatment can help patients explore the etiology of their symptoms.

The SAMSON study was funded by the British Heart Foundation, the United Kingdom's (U.K.) cardiovascular charity.

Presenter: Dr. Robert S. Rosenson Key Points: Evinacumab, whether administered intravenously or subcutaneously, significantly reduced LDL-C, by greater than 50% at the highest dose levels, as compared to placebo, and the drug was generally well-tolerated.

Patients who have hypercholesterolemia that persists despite maximally tolerated statins, week 16, the baseline-adjusted least-squares mean differences were -56.0% (450 mg weekly), -52.9% (300 mg weekly) and -38.5% (300 mg every 2 weeks; all groups, p<0.0001). The placebo group saw an increase in LDL-C level (+8.8%).

The investigators reported that most patients receiving either subcutaneous or intravenous evinacumab experienced adverse events at higher rates than those receiving the respective J o u r n a l P r e -p r o o f Journal Pre-proof placebos. Adverse events in the subcutaneous groups that occurred more commonly in the evinacumab vs. placebo groups were urinary tract infection (evinacumab 11% vs. placebo 8%), injection-site erythema (6% vs. 3%), arthralgia (5% vs. 3%) and myalgia (5% vs. 0%). Adverse events in the intravenous groups that occurred more commonly in the evinacumab vs. placebo groups were abdominal pain (evinacumab 6% vs. placebo 0%), back pain (7% vs. 6%), dizziness (7% vs. 0%), fatigue (7% vs. 6%), arm or leg pain (7% vs. 6%), nausea (7% vs. 0%) and nasopharyngitis (12% vs. 6%). However, few adverse events were serious, and there were no clinically significant differences between the treatment and placebo groups in both subcutaneous and intravenous administrations.

Only one event that resulted in stoppage of treatment in the subcutaneous group was related to the trial drug: dyspnea, in the evinacumab 300 mg every 2 weeks dosage group, and was fully resolved. One patient who received 300 mg of evinacumab weekly died of heart failure or cardiogenic shock, and one in the 300 mg every 2 weeks group died of sudden cardiac death.

These patients had underlying heart disease, and their deaths were not considered to be related to evinacumab. In the intravenous groups, there was one serious adverse event that led to treatment stoppage and was related to the trial drug, anaphylactic reaction, which occurred with the second dose of 15 mg/kg of evinacumab. The reaction was resolved with oral diphenhydramine the same plaque. CMR was abnormal in 74.1% of the 116 patients imaged through that modality. CMR showed an ischemic pattern (infarction or myocardial edema in a coronary territory) in 53.4% of patients undergoing CMR and a non-ischemic pattern (myocarditis, takotsubo syndrome or nonischemic cardiomyopathy) in 20.7%. Clinicians were able to identify a cause of MINOCA in 84.5% (98/116) of the women who underwent both OCT and CMR (95% CI, 76.3% to 90.3%). This rate was significantly higher than in patients who underwent OCT alone (51/116 = 44.0%; 95% CI, 34.9% to 53.5%; p<0.001) or CMR alone (86/116 = 74.1%, 95% CI, 65.0% to 81.6%; p=0.001).

Reynolds concluded that their study shows the mechanisms of MINOCA are similar to MI with obstructive coronary artery disease, specifically atherothrombosis with a possible contribution of coronary artery spasm.

The study's limitations included that the sample size was relatively small and there were very few ST-elevation myocardial infarction (STEMI) cases. Myocardial edema is a single coronary territory that is considered evidence of ischemic injury, but it does not rule out regional myocarditis. There was no spasm testing, no control group, and not all of the women had threevessel OCT and CMR. Finally, the study was limited to women, meaning there was no comparison with men. In the trial, patients who were considered for revascularization with DES were enrolled in 23 centers in South Korea. Between December 2015 and September 2019, a total of 3020 patients were randomized to receive either 1-month DAPT followed by aspirin monotherapy after receiving BioFreedom, a polymer-free Biolimus A9-coated stent (1-month DAPT group, n=1507), or 6 to 12 months of DAPT followed by aspirin monotherapy after implantation with BioMatrix (biodegradable-polymer, Biolimus A9-coated) or Ultimaster (biodegradable-polymer, sirolimus-eluting) stents (6-12 months DAPT group, n=1513).

The primary endpoint was a 1-year composite of cardiac death, nonfatal MI, TV revascularization, cerebrovascular accident, or major bleeding. The estimated event rate for patients in the 6-12 month DAPT group was 6.2%. A 3% noninferiority margin was prespecified, giving the study 90% power with a one-sided alpha error rate of 2.5% and allowing for at least 10% loss to follow-up, which required a sample size of 3020 patients. Noninferiority could be declared if the upper limit of the one-sided 97.5% CI for the difference in primary endpoint incidences between the groups was less than 3%.

Of the 3020 patients who were randomized, 1507 were assigned to the 1-month group and 1513 were assigned to the 6-12 month group. At baseline, the groups were well-matched. Patients in both groups had a mean age of 67 years, and 69% were men. About 60% of study patients presented with stable angina. About 17% of patients in the 1-month group did not adhere to the DAPT regimen. A total of 2969 patients completed 1-year follow-up. An analysis found no significant difference in the number of cardiac events between the two groups: The 1-month group had a 5.9% composite event rate compared to 6.5% in the 6-12 month treatment group.

James De Lemos, MD, PhD. The latest analyses cover data running from the registry's inception on April 3 through July 31, 2020, for which clean data were available in approximately 9000 patients. As of November 9, 2020, the study included 109 hospitals across 35 US states, with more than 22,500 patient records.

The COVID-19 pandemic has driven severe outcomes in some patients, killing more than 1. that patients admitted to hospital with COVID-19 are notably more obese than that US population. In particular, there was a higher prevalence of Class III (severe) obesity, at 11% in the AHA registry compared to 7% in the general population as recorded by NHANES.

The differences were magnified among people younger than 50 years, an age group in which obesity is dramatically over-represented in hospitalized COVID-19. In particular, the probability of BMI greater than 40 kg/m 2 in the AHA registry was double that of the overall population younger than 50. There were "striking differences" in age between hospitalized patients of a normal weight and the severely obese, who were almost 20 years younger, he added. The interaction between BMI and age can also clearly be seen for in-hospital death rates and mechanical ventilation (as a function of BMI). The relationship is attenuated and not significant among middle-aged and older adults. Severely obese people are at a mechanical disadvantage when it comes to pulmonary morbidity and the virus's purported effects on the renin-angiotensin system, which is already dramatically upregulated for obesity.

The findings have important public health implications as the pandemic surges. This calls for "clear public health messaging for younger obese individuals who may have received the false message that they are at low risk for severe COVID infection," De Lemos said. In addition, severely obese individuals, including young people, should be considered at higher risk for infection and, therefore, could warrant prioritization for vaccination.

Data from the AHA COVID-19 CVD Registry also highlighted the endemic national issue of systemic racism, with Black and Hispanic people making up the majority (58%) of hospitalized cases in the corresponding analyses of around 8000 individuals. In the study of racial and ethnic differences in presentation and outcomes for patients hospitalized with COVID-19, the investigators compared those enrolled in the AHA registry with census-tracked data from the hospitals where those patients were admitted.

The percentage of Black and Hispanic people hospitalized with COVID-19 in the AHA registry, 58%, is a much larger proportion than in the communities where the hospitalizations occur.

Black and Hispanic patients admitted to the hospital were younger than white patients by 9 and 12 years, respectively, while the probability of patients being uninsured or self-payers was significantly higher than in White people (non-Hispanic White 2.5%, non-Hispanic Black 4.5%, Hispanic all races 12.8%). Obesity, diabetes, and hypertension were more prevalent in Black and Hispanic people. Black patients were also over-represented in the obesity study, in the group with Class III severe obesity, making up 40% of the total.

Nevertheless, once in the hospital, race and ethnicity were not independently associated with worse outcomes, although Black and Hispanic patients did clearly face disproportionate mortality and morbidity because of higher rates of hospitalization. The figures show an issue with disparities in care upstream of the hospitalization event.

In the overall analysis of data from the AHA COVID-19 CVD Registry, researchers were surprised to find that in-hospital cardiovascular complications were less common than originally J o u r n a l P r e -p r o o f

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients with High Cardiovascular Risk

Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Statin vs Placebo vs No Treatment: n-of-1 Trial of Patient Symptoms: The SAMSON Trial

Placebo, or No Treatment to Assess Side Effects

The Efficacy and Safety of Evinacumab in Patients with Refractory Hypercholesterolemia

Evinacumab in Patients with Refractory Hypercholesterolemia

Coronary OCT and Cardiac MRI to Determine Underlying Causes of MINOCA in Women

Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women

Novel Healing-Targeted DES with Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation after DES Implantation in Coronary Artery Disease

One-month dual antiplatelet therapy followed by aspirin monotherapy after drug-eluting stent implantation: Randomized One-Month DAPT trial

Early Coronary CT Angiography in Patients with Suspected or Provisionally Diagnosed Acute Coronary Syndrome: The RAPID CTCA trial

Findings from the AHA COVID-19 CVD Registry